Item 4 — Purpose of Transaction
Item 4 of the Schedule 13D filed by the Reporting Person on December 27, 2024 (the "Schedule 13D"), is incorporated by reference herein. On November 6, 2024, the Issuer announced that the Issuer had entered into a transaction agreement (the "Transaction Agreement") to acquire all the shares of capital stock of T1 G1 Dallas Holding and its related subsidiaries (the "Trina Business Combination"). The Issuer granted certain anti-dilution rights to the Reporting Person in connection with the Trina Business Combination (the "Trina Anti-Dilution Rights"). On October 31, 2025, the Issuer entered into an Amended and Restated Stock Purchase Agreement (the "Stock Purchase Agreement") with certain purchasers pursuant to which, among other things, the Issuer issued 21,504,901 shares of common stock, 1,600,000 shares of the Issuer's Series B Convertible Non-Voting Preferred Stock, par value $0.01 per share (the "Series B Preferred Stock"), and 5,000,000 shares of the Issuers Series B-1 Convertible Non-Voting Preferred Stock, par value $0.01 per share (the "Series B-1 Preferred Stock" and together with the Series B Preferred Stock, the "Outstanding Preferred Stock"), at a price of $10.00 per share of Series B-1 Preferred Stock. In connection with the Stock Purchase Agreement, the Reporting Person informed the Issuer of its intention to subscribe for an additional 4,274,704 shares of common stock at a subscription price of $1.70 per share pursuant to the Trina Anti-Dilution Rights. The subscription for such shares of common stock pursuant to the Trina Anti-Dilution Rights closed on January 21, 2026.